March 12, 2026
1 min read

Virta Health’s Nutrition Therapy Extends Survival by 34% in Stage IV Pancreatic Cancer Patients, New Clinical Trial Shows

DENVER, March 12, 2026–Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced pancreatic cancer is treated. Conducted in partnership with USC Norris Comprehensive Cancer Center, Mayo Clinic, HonorHealth Research Institute, and others, the study was peer-reviewed and published in Cancer, revealing that Virta’s medically supervised, individualized nutriti

Leave a Reply

Your email address will not be published.

Previous Story

After China outlay, Lilly plugs $126M into Japan manufacturing plant expansion

Next Story

An NIH whistleblower warning

Previous Story

After China outlay, Lilly plugs $126M into Japan manufacturing plant expansion

Next Story

An NIH whistleblower warning

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop